2009 & 2005 Program Project Development Grant Recipient – Andrew Berchuck
Andrew Berchuck, M.D.
International Ovarian Cancer Association Consortium: Finding Genetic Markers of Ovarian Cancer Using Polymorphisms
While some ovarian cancers arise in women with inherited mutations in the BRCA1 or BRCA2 genes, the genetic changes responsible for most ovarian cancers, which are not inherited, remains unknown. Understanding these latter genetic changes could lead to better diagnostics and treatment for the disease. Dr. Berchuck is the Principal Investigator of the International Ovarian Cancer Association Consortium (OCAC)—that includes researchers at 19 institutions in the U.S., the U.K., and Australia–which aims to find subtle genetic changes, called polymorphisms, that may exist and predispose women to ovarian cancer. Because such polymorphism studies require large populations to compare women with ovarian cancer to woman who have not had the disease, the International OCAC was founded to facilitate the collaboration to get study subjects. The other goals of the OCAC are: finding ovarian cancer-susceptibility polymorphisms, understanding the relationship between polymorphisms and hormone pathways and investigating the links between known risk factors for ovarian cancer and polymorphisms.
Andrew Berchuck, M.D. is Co-Director of the Duke Comprehensive Cancer Center Breast/Ovarian Cancer Program. He also serves as the Director of Gynecologic Cancer Research.
Dr. Berchuck has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) using microarrays to define molecular signatures that are predictive of clinical phenotypes and response to targeted biological therapies.
Dr. Berchuck attended medical school and received his Obstetrics and Gynecology residency training at Case Western Reserve University in Cleveland, Ohio. His research and clinical training in Gynecologic Oncology was completed at UT Southwestern in Dallas, Texas and Memorial Sloan-Kettering Cancer Center in New York City.
Selected Recent Press
Catching Ovarian Cancer Early May Miss Aggressive Tumors
New Gene Mutation for Ovarian Cancer Found (download press release)
The five-year survival rate for ovarian cancer has increased by only 8% in the last 30 years.
We are at a critical crossroads for supporting research into unlocking the mysteries of ovarian cancer. You can make a difference by supporting the research of the Ovarian Cancer Research Fund.
Help us find a cure for ovarian cancer. Donate online and make a difference.